Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Mary Beth Dooley | Principal Executive Officer & Principal Financial Officer | -- | -- | 1982 |
| Dr. Timothy K. Lu M.D., Ph.D. | Co-Founder & Member of Scientific Advisory Board | -- | -- | 1981 |
| Dr. James J. Collins Ph.D. | Co-Founder & Member of Scientific Advisory Board | -- | -- | 1967 |
| Dr. Jose-Carlos Gutierrez-Ramos Ph.D. | Advisor | 597.13k | -- | 1962 |
Synlogic, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 1
Description
Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts.
Corporate Governance
Upcoming Events
May 12, 2025 at 12:30 PM UTC - May 16, 2025 at 12:30 PM UTC
Synlogic, Inc. Earnings Date